Abstract
Head and neck squamous cell carcinomas (HNSCC) are aggressive and heterogenous tumors with a high fatality rate. Many gene signatures (GS) have been developed with both prognostic and predictive significance. We aimed to externally validate five published GS in a large European collection of HNSCC patients. Gene expression from 1097 treatment-naïve HNSCC patients’ primary tumors was used to calculate scores for the five GS. Cox proportional hazard models were used to test the association between both 2-year overall survival and 2-year disease-free survival and the signature scores. The predictive role of GS was validated by comparing survival associations in patients receiving specific treatment (i.e., radiotherapy, systemic treatment) versus those who did not. We successfully externally validated all 5 GS, including two prognostic signatures, one signature as prognostic and predictive of sensitivity to systemic treatment, while signatures for cisplatin-sensitivity and radiosensitivity were validated as prognostic only.
Competing Interest Statement
M.L. reports receiving a speaker fee from MSD unrelated to the content of this work. L.L. declares the following conflicts of interest, all unrelated to the content of this work: research funds donated directly to the institute for clinical trials from AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, Hoffmann-La Roche Ltd, IRX Therapeutics, Medpace, Merck-Serono, MSD, Novartis, Pfizer, Roche, and Buran; occasional fees for participation as a speaker at conferences/congresses or as a scientific consultant for advisory boards from AstraZeneca, Bayer, MSD, Merck-Serono, AccMed, Neutron Therapeutics, Inc., and Alentis. S.C. declares occasional fees for participation as a speaker at conferences/congresses from AccMed; support for attending meetings and/or travel from AccMed, MultiMed Engineers srl, Care Insight sas, unrelated to the content of this work. All remaining authors declare no competing interests.
Funding Statement
This work is part of the research project "Supporting Personalized Treatment Decisions in Head and Neck Cancer through Big Data (SuPerTreat)" funded within ERA PerMed JTC2019 Joint transnational call for proposals (2019) for "Personalised medicine: multidisciplinary research Toward implementation", research grant nr. ERAPERMED2019-281 and supported by FRRB (Fondazione Regionale per la Ricerca Biomedica), BMBF (Bundesministerium fur Bildung und Forschung), RCN (Norges forskningsråd), ANR (Agence nationale de la recherche) and GSRT (General Secretariat for Research and Technology). MM-S received funding from the European Union's Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie Actions Grant, agreement No. 80113 (Scientia fellowship). BD2Decide received funding from the European Union Horizon 2020 Framework Programme, Grant/Award Number: 689715.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in full accordance with the World Medical Association's Declaration of Helsinki (2013 version). The protocol was ethically approved by the Norwegian Regional Committee for Medical and Health Research Ethics (REK) South-East A under application number 270467. All proprietary studies that contributed data obtained ethical approval from their respective local authorities in Italy, Germany, or France. Copies of these ethical approvals were provided to the principal investigator by the data providers. BD2Decide was approved by the Ethical Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) in 2016 and it has two identifiers: INT65-16 and INT66-16. Biomarker analysis of the ARO 04-01 Def-RCT cohort was approved by the Ethical Committee of the Charite - Universitatsmedizin Berlin (Berlin, Germany) in 2010 (EA2/086/10). Biomarker analysis of the DKTKRO Def-RCT was approved by the Ethical Committee of the Technical University of Dresden (Dresden, Germany) in 2014 (EK200112014).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
5. Data availability
The SuPerTreat dataset is hosted by the Services for Sensitive Data (TSD) at the University of Oslo. Anonymized data containing only the survival endpoints and gene signature scores will be uploaded to Zenodo prior to publication. Access to the original data may be granted by the data owners upon application.
